- Stephane Debono, EVP, Diagnostics BU and CEO of HalioDx Inc., is appointed Deputy CEO
- Philippe Mourere joins the Executive Committee as SVP Commercial and Business Development
HalioDx SAS, the immuno-oncology diagnostic company, today announced a change in its leadership team with the appointment of Stephane Debono as Deputy CEO and of Philippe Mourere as Senior Vice President Commercial and Business Development.
Stéphane Debono brings more than 25 years of experience in the IVD Industry. He becomes Deputy CEO of HalioDx. Stéphane Debono is a co-founder of HalioDx, and with his expanded responsibilities will now oversee the daily operations and growth of HalioDx.
Philippe Mourere brings over 20 years of experience as a senior sales, marketing and business development executive from both large and mid-size global Life Science companies, with a focus on growth strategies in highly specialized genomics, proteomics, personalized medicine and digital pathology markets. US-based, he will lead commercial and business development with an immediate concentration on the US expansion of HalioDx Pharma & Diagnostic Businesses.
In his most recent positions, Philippe Mourere was Sr. Vice President Commercial Operations at Ultivue, a developer of tissue biomarker assays for translational research where he had a major role in developing and executing full commercialization strategy of the company, actively participating to the growth of multiplexed tissue marker immuno-profiling business.
Vincent Fert, Chairman and CEO of HalioDx, said “I have been working with Stéphane for 20 years; his comprehensive and successful IVD experience, his business acumen and strong leadership style is the perfect skill-set to lead HalioDx international operations to the next level. Philippe brings us a strong track record in driving value-generating business development initiatives and in commercial operations that will complement our leadership team. Over the past 5 years, HalioDx has continuously delivered above expectations, and we are planning to accelerate our growth in the next years, with a special focus on the commercial execution notably in the US market”.